Key result
Pretreatment with recombinant human erythropoietin significantly prevented functional damage and electrophysiologic injury induced by acute doxorubicin or trastuzumab exposure in isolated rat hearts.
Why the study?
Does pretreatment with rhEPO prevent acute cardiotoxicity induced by doxorubicin and trastuzumab in isolated rat hearts?
Does pretreatment with rhEPO prevent acute cardiotoxicity induced by doxorubicin and trastuzumab in isolated rat hearts?
Pretreatment with rhEPO protects isolated rat hearts against functional and electrophysiologic damage induced by acute exposure to doxorubicin or trastuzumab.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for rhEPO cardioprotection; human trials needed before any clinical consideration.
Ramond et al. (2008) studied Acute chemotherapy cardiotoxicity. Recombinant human erythropoietin (rhEPO) vs. Vehicle was evaluated on Left ventricular developed pressure, end diastolic pressure, coronary perfusion pressure, and incidence of ventricular tachycardia or fibrillation. Pretreatment with recombinant human erythropoietin significantly prevented functional damage and electrophysiologic injury induced by acute doxorubicin or trastuzumab exposure in isolated rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: